← Research library

Thymopentin versus placebo in moderate-to-severe atopic dermatitis

Randomized study in people · 1990

What was studied
100 participants randomized at two centers. Thymopentin n=48 and placebo n=52. Pruritus analysis included 47 and 45, respectively.
Main finding
Itch improved at week six · 31/47 (66%) with thymopentin versus 18/45 (40%) with placebo (p=0.02).

Reported findings and study design

Reported findings

Double-blind comparison of 50 mg subcutaneous thymopentin daily for six weeks against placebo, followed by four weeks off treatment. Participants could continue topical corticosteroids and oral antihistamines.

Population or model 100 participants randomized at two centers. Thymopentin n=48 and placebo n=52. Pruritus analysis included 47 and 45, respectively.

Dose, route and schedule

Double-blind comparison of 50 mg subcutaneous thymopentin daily for six weeks against placebo, followed by four weeks off treatment. Participants could continue topical corticosteroids and oral antihistamines.

Protocol source ↗ · Original report, including the pruritus and safety results.

Results · Original report, including the pruritus and safety results.
MeasureResultComparison, timing and statistics
Itch improved at week six31/47 (66%) with thymopentin versus 18/45 (40%) with placebo (p=0.02).
Itch improved by at least two grades11/47 versus 2/45 (p=0.01).
Affected body areaRelative decline of 17% versus 4% (p=0.04). Overall severity also favored thymopentin (p=0.04).
Adverse experiences14/48 versus 10/52 reported an adverse experience. The between-group difference was not statistically significant.
Six-week pruritus results
Six-week pruritus results
OutcomeThymopentin (n=47)Placebo (n=45)Reported p
Any improvement31 (66%)18 (40%)0.02
Improvement of at least two grades1120.01
Worsening43—

More placebo recipients withdrew, and the week-six pruritus analysis used available observations. Symptoms showed a trend toward rebound after injections stopped. The trial did not measure long-term control.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • More placebo recipients withdrew, and the week-six pruritus analysis used available observations. Symptoms showed a trend toward rebound after injections stopped. The trial did not measure long-term control.

Source details

Original report, including the pruritus and safety results.

Sources checked

Added to the library

Citation

Randomized trialFull text available

D. Y. Leung, R. L. Hirsch, L. Schneider, C. Moody, R. Takaoka, S. H. Li, L. A. Meyerson, S. G. Mariam, G. Goldstein, J. M. Hanifin. Thymopentin versus placebo in moderate-to-severe atopic dermatitis Journal of Allergy and Clinical Immunology 85(5), 927–933

Study source ↗ · DOI 10.1016/0091-6749(90)90079-J · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards